Shandong Sinobioway Biomedicine Co., Ltd. (SHE:002581)

SHE:002581 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	445.01	506.4	151.91	183.8	187.8	284.15
Cash & Short-Term Investments	445.01	506.4	151.91	183.8	187.8	284.15
Cash Growth	106.63%	233.35%	-17.35%	-2.13%	-33.91%	-74.65%
Accounts Receivable	75.94	93.32	172.62	179.72	272.96	353.77
Other Receivables	101.18	52.24	78.87	18.36	13.49	16.75
Receivables	177.12	145.55	251.49	198.09	286.45	370.52
Inventory	87.71	79.64	85.31	80.04	64.33	70.87
Other Current Assets	20.04	15.41	7.99	56.43	29.88	40.62
Total Current Assets	729.88	747.01	496.71	518.36	568.45	766.16
Property, Plant & Equipment	272.71	274.74	357.84	705.47	713.76	684.72
Long-Term Investments	1,049	1,056	1,355	1,503	1,223	751.21
Other Intangible Assets	91.65	93.47	108.29	126.32	134.29	144.55
Long-Term Deferred Tax Assets	12.85	11.21	6.12	11.84	25.28	25.14
Long-Term Deferred Charges	0.28	0.32	1.41	5.2	7.78	7.72
Other Long-Term Assets	11.66	13.44	12.26	0.49	83.36	65.46
Total Assets	2,168	2,196	2,337	2,870	2,756	2,445
Accounts Payable	25.89	35.35	73.69	43.64	42.13	14.46
Accrued Expenses	4.62	20.83	22.5	19.32	31.01	32.34
Short-Term Debt	2.3	2.77	13.84	150.42	151.54	118.5
Current Portion of Leases	-	0.17	-	13.46	15.83	20.82
Current Income Taxes Payable	1.78	-	0.95	1.2	0.44	0.65
Current Unearned Revenue	27.25	10.46	3.59	26.86	3.43	1.21
Other Current Liabilities	29.2	13.03	19.03	109.38	14.17	18.9
Total Current Liabilities	91.04	82.61	133.61	364.28	258.54	206.87
Long-Term Leases	4.01	-	0.71	1.47	9.8	27.77
Long-Term Unearned Revenue	5.49	5.49	5.49	6.71	9.74	10.96
Long-Term Deferred Tax Liabilities	10.42	9.39	7.51	7.68	8.68	8.74
Other Long-Term Liabilities	79.73	76.12	16.09	9.67	-	-
Total Liabilities	190.69	173.61	163.41	389.82	286.76	254.33
Common Stock	229.15	229.15	229.15	229.15	229.15	229.15
Additional Paid-In Capital	871.01	866.41	873.93	858.5	858.29	858.29
Retained Earnings	791.23	828.08	965.39	1,298	1,301	1,030
Total Common Equity	1,891	1,924	2,068	2,385	2,388	2,117
Minority Interest	85.77	98.67	105.26	94.94	81.11	73.43
Shareholders' Equity	1,977	2,022	2,174	2,480	2,469	2,191
Total Liabilities & Equity	2,168	2,196	2,337	2,870	2,756	2,445
Total Debt	6.31	2.94	14.55	165.35	177.16	167.09
Net Cash (Debt)	438.7	503.47	137.36	18.45	10.64	117.06
Net Cash Growth	114.16%	266.52%	644.38%	73.50%	-90.91%	-43.55%
Net Cash Per Share	0.66	0.76	0.21	0.03	0.02	0.18
Filing Date Shares Outstanding	659.22	659.74	659.74	659.74	659.74	659.74
Total Common Shares Outstanding	659.22	659.74	659.74	659.74	659.74	659.74
Working Capital	638.84	664.4	363.1	154.08	309.91	559.3
Book Value Per Share	2.87	2.92	3.14	3.62	3.62	3.21
Tangible Book Value	1,800	1,830	1,960	2,259	2,254	1,973
Tangible Book Value Per Share	2.73	2.77	2.97	3.42	3.42	2.99
Buildings	-	393.55	486.08	639.62	612.92	426.35
Machinery	-	431.4	432.25	413.16	424.47	345.34
Construction In Progress	-	38.11	22.17	91.43	64.86	353.63

Source: S&P Global Market Intelligence. Standard template. Financial Sources.